DE60142684D1 - Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen - Google Patents
Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellenInfo
- Publication number
- DE60142684D1 DE60142684D1 DE60142684T DE60142684T DE60142684D1 DE 60142684 D1 DE60142684 D1 DE 60142684D1 DE 60142684 T DE60142684 T DE 60142684T DE 60142684 T DE60142684 T DE 60142684T DE 60142684 D1 DE60142684 D1 DE 60142684D1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- autoreactive
- blocking
- destruction
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 230000000903 blocking effect Effects 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 abstract 5
- 102100038081 Signal transducer CD24 Human genes 0.000 abstract 4
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 102000044489 human CD24 Human genes 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19281400P | 2000-03-29 | 2000-03-29 | |
| PCT/US2001/040390 WO2001072325A1 (en) | 2000-03-29 | 2001-03-29 | Methods of blocking tissue destruction by autoreactive t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60142684D1 true DE60142684D1 (de) | 2010-09-09 |
Family
ID=22711138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60142684T Expired - Lifetime DE60142684D1 (de) | 2000-03-29 | 2001-03-29 | Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267909B1 (de) |
| JP (1) | JP2004500110A (de) |
| AT (1) | ATE475428T1 (de) |
| AU (2) | AU5979201A (de) |
| CA (1) | CA2404340C (de) |
| DE (1) | DE60142684D1 (de) |
| DK (1) | DK1267909T3 (de) |
| WO (1) | WO2001072325A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030106084A1 (en) | 2000-03-29 | 2003-06-05 | Yang Liu | Methods of blocking tissue destruction by autoreactive T cells |
| ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
| BR112015000310A2 (pt) * | 2012-07-13 | 2017-06-27 | Univ Pennsylvania | conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| CN107207597A (zh) * | 2014-11-06 | 2017-09-26 | 儿研所儿童医学中心 | 用于癌症和自身免疫疾病的免疫疗法 |
| CN107531772B (zh) * | 2015-05-07 | 2021-09-21 | 肿瘤免疫股份有限公司 | Cd24用于降低低密度脂蛋白胆固醇水平的用途 |
| EP3334449B1 (de) * | 2015-08-10 | 2021-09-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Verfahren und pharmazeutische zusammensetzungen zur verbesserung der wundheilung mithilfe von cd24 |
| US10799558B2 (en) * | 2016-02-02 | 2020-10-13 | Oncoimmune, Inc. | Use of CD24 proteins for treating leptin-deficient conditions |
| AU2018231166A1 (en) * | 2017-03-07 | 2019-09-26 | Oncoimmune, Inc. | Methods of use of soluble CD24 for treating systemic lupus erythematosus |
| WO2018213266A1 (en) * | 2017-05-15 | 2018-11-22 | Oncoimmune, Inc. | Methods of use of soluble cd24 for neuroprotection and remyelination |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
-
2001
- 2001-03-29 DK DK01933358.2T patent/DK1267909T3/da active
- 2001-03-29 JP JP2001570286A patent/JP2004500110A/ja active Pending
- 2001-03-29 DE DE60142684T patent/DE60142684D1/de not_active Expired - Lifetime
- 2001-03-29 AU AU5979201A patent/AU5979201A/xx active Pending
- 2001-03-29 WO PCT/US2001/040390 patent/WO2001072325A1/en not_active Ceased
- 2001-03-29 AT AT01933358T patent/ATE475428T1/de not_active IP Right Cessation
- 2001-03-29 EP EP01933358A patent/EP1267909B1/de not_active Expired - Lifetime
- 2001-03-29 AU AU2001259792A patent/AU2001259792B2/en not_active Ceased
- 2001-03-29 CA CA2404340A patent/CA2404340C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004500110A (ja) | 2004-01-08 |
| ATE475428T1 (de) | 2010-08-15 |
| CA2404340A1 (en) | 2001-10-04 |
| WO2001072325A9 (en) | 2003-02-20 |
| EP1267909A1 (de) | 2003-01-02 |
| DK1267909T3 (da) | 2010-11-08 |
| WO2001072325A1 (en) | 2001-10-04 |
| AU5979201A (en) | 2001-10-08 |
| CA2404340C (en) | 2012-10-16 |
| EP1267909A4 (de) | 2006-05-03 |
| EP1267909B1 (de) | 2010-07-28 |
| AU2001259792B2 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0008161A (pt) | Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral | |
| DE60142684D1 (de) | Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen | |
| JPH04507195A (ja) | 腫瘍壊死因子結合リガンド | |
| ATE309360T1 (de) | Vaskularer endothelialer wachstumsfaktor 2 | |
| DE69932084D1 (de) | Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen | |
| KR927003816A (ko) | Cd3에 대한 항체 | |
| EP1140175A4 (de) | Antikörper gegen verkürzten vegf-d und deren verwendungen | |
| McComb et al. | Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. | |
| DE602004032328D1 (de) | Medizinische verwendung von anti-cs1 antikörpern | |
| EP0837696A4 (de) | Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort | |
| FI973120A0 (fi) | Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa | |
| MA28418B1 (fr) | Anticorps liant un recepteur de l'interleucine 4 | |
| DE69309472D1 (de) | Fusionsproteine von monomeren und dimeren von antikörperfragmenten | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| ES2180754T3 (es) | Compuestos y metodos para la deteccion de infeccion por t. cruzi. | |
| DK0536275T3 (da) | Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf | |
| MX9708008A (es) | Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. | |
| SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
| DE69632465D1 (de) | Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung | |
| ATE132197T1 (de) | Monoklonale antikörper | |
| EP1003552A4 (de) | LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM | |
| ATE252637T1 (de) | Antikörper gegen lymphozyten-assoziiertes zelloberflächenprotein | |
| DE69638024D1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
| Alshoubaki et al. | A superior extracellular matrix binding motif to enhance the regenerative activity and safety of therapeutic proteins | |
| AR003941A1 (es) | Anticuerpos monoclonales humanos neutralizadores de hiv-1 |